3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line TherapyAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, clear cell adenocarcinoma, endocrine system disorder, epithelial neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinomaRecruitingPhase 22026-07-27NCT05460000
Early Detection of OAB and Elimination of Negative Impact on Quality of LifeFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, overactive bladder, urinary bladder disorder, urinary system disorderRecruitingNot applicable2026-01-27NCT07371000
A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live SettingPlaque PsoriasisActive, not recruitingNot stated2025-06-24NCT06488170